Viking Therapeutics, Inc.
NASDAQ:VKTX
34.86 (USD) • At close January 15, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Viking Therapeutics, Inc. |
Symbool | VKTX |
Munteenheid | USD |
Prijs | 34.86 |
Beurswaarde | 3,884,658,960 |
Dividendpercentage | 0% |
52-weken bereik | 20.28 - 99.41 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Brian Lian Ph.D. |
Website | https://www.vikingtherapeutics.com |
An error occurred while fetching data.
Over Viking Therapeutics, Inc.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)